The Impact of Treatment-Resistant Depression on Health Care Utilization and Costs
The DOI matches its Crossref record.
Abstract
BACKGROUND: Approximately 50% of patients diagnosed with major depressive disorder will experience a recurrent or chronic course of illness for which long-term treatment is recommended. Moreover, at least 20% of patients diagnosed with depression do not respond satisfactorily to several traditional antidepressant medication treatment trials. Very little is known about the health care costs of patients with treatment-resistant depression. METHOD: Based on medical claims data (MarketScan Research Database, The MEDSTAT Group, Cambridge, Mass.) from January 1, 1995, to June 30, 2000, a naturalistic, retrospective analysis was conducted to study the characteristics and health care utilization of patients with treatment-resistant depression. All patients having an International Classification of Diseases, Ninth Revision (ICD-9), diagnosis code for unipolar or bipolar depression with specified antidepressant dosing and treatment durations were initially selected. Patients were then classified as "treatment resistant" if either they switched from or augmented initial antidepressant medication with other antidepressants at least twice (outpatient treatment-resistant group) or they switched from or augmented their initial antidepressant medication and also had a claim for either a depression-related hospitalization or suicide attempt (hospitalized treatment-resistant group). Those meeting the initial medication and diagnosis selection criteria but not meeting the treatment-resistance criteria constituted the comparison group. Members of the comparison group had comparatively stable antidepressant medication use patterns, consistent with an acceptable response to treatment. Patients were followed for a minimum of 9 months. Resource utilization was calculated from index date to last available claims data point and then annualized. RESULTS: Treatment-resistant patients were more likely to be diagnosed with bipolar disorder or concurrent substance abuse or anxiety disorders than the comparison group (p <.001). Treatment-resistant patients were at least twice as likely to be hospitalized (general medical and depression related) and had at least 12% more outpatient visits (p <.02). Treatment resistance was also associated with use of 1.4 to 3 times more psychotropic medications (including antidepressants) (p <.001). Patients in the hospitalized treatment-resistant group had over 6 times the mean total medical costs of non-treatment-resistant depressed patients ($42,344 vs. $6512) (p <.001) and their total depression-related costs were 19 times greater than those of patients in the comparison group ($28,001 vs. $1455) (p <.001). CONCLUSION: Treatment-resistant depression is costly and associated with extensive use of depression-related and general medical services. These findings underscore the need for early identification and effective long-term maintenance treatment for treatment-resistant depression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, for approximately 50% of those who suffer from depression, their illness will follow a chronic, relapsing course associated with considerable disability and impairment (Crown 2002).”
From Interventions for preventing relapse and recurrence of a depressive disorder in children and adolescents (2012) · cites this paper as Crown 2002
In the citing paper
“Direct medical costs associated with TRD are estimated to be 2-6 times higher compared with other patients with MDD, 42, 43 with costs increasing with chronicity and severity of TRD. 44”
From Treatment resistance in psychiatry: state of the art and new directions (2022) · cites this paper as [43]
In the citing paper
“Patients with TRD are twice as likely to be hospitalised compared with non-TRD patients, and require increased numbers of psychiatric outpatient visits. 43”
From Treatment resistance in psychiatry: state of the art and new directions (2022) · cites this paper as [43]
Citations
Cited by
Shippee, N. D., Shah, N. D., May, C. R., Mair, F. S., & Montori, V. M. (2012) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2012.05.005 · Cited by 728
Subcallosal Cingulate Deep Brain Stimulation for Treatment-Resistant Unipolar and Bipolar Depression
Holtzheimer, P. E. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.1456 · Cited by 608
“Patients were taking a mean (SD) of 3(2) psychotropic medications at the time of surgery.”
BackgroundMethodMillan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
(2007) · PubMed · Cited by 453
Defining treatment‐resistant depression
Gaynes, B. N., Lux, L., Gartlehner, G., Asher, G., Forman‐Hoffman, V., Green, J., Boland, E., Weber, R. P., Randolph, C., Bann, C., et al. (2020) · Depression and Anxiety · doi:10.1002/da.22968 · Cited by 447
“Individuals with TRD are twice as likely to be hospitalized; the cost of this hospitalization is more than six times the mean total cost for depressed patients who are not treatment‐resistant (Crown et al., 2002).”
BackgroundManagement of Treatment-Resistant Depression: Challenges and Strategies
Voineskos, D., Daskalakis, Z. J., & Blumberger, D. M. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s198774 · Cited by 446
“Chronically depressed patients have a lower chance of recovery, 98 and often suffer from TRD. 25,87 Challenges in Assessing TRD One of the perils of diagnosing TRD is that of “ pseudo-resistance ” .”
Treatment resistance in psychiatry: state of the art and new directions
Howes, O. D., Thase, M. E., & Pillinger, T. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01200-3 · Cited by 413
Birnbaum, H. G., Kessler, R. C., Kelley, D., Ben-Hamadi, R., Joish, V. N., & Greenberg, P. E. (2010) · Depression and Anxiety · doi:10.1002/da.20580 · Cited by 380
The Role of CREB in Depression and Antidepressant Treatment
Blendy, J. A. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.11.003 · Cited by 365
Burden of illness in Parkinson's disease
Huse, D. M., Schulman, K., Orsini, L., Castelli‐Haley, J., Kennedy, S., & Lenhart, G. (2005) · Movement Disorders · doi:10.1002/mds.20609 · Cited by 335
Economic burden of metastatic bone disease in the U.S.
Schulman, K. L., & Kohles, J. (2007) · Cancer · doi:10.1002/cncr.22678 · Cited by 241
Jaffe, D. H., Rive, B., & Denee, T. R. (2019) · BMC Psychiatry · doi:10.1186/s12888-019-2222-4 · Cited by 237
The role of ketamine in treatment-resistant depression: A systematic review
Serafini, G., Howland, R., Rovedi, F., Girardi, P., & Amore, M. (2014) · Current Neuropharmacology · doi:10.2174/1570159x12666140619204251 · Cited by 234
Réus, G. Z., Jansen, K., Titus, S., Carvalho, A. F., Gabbay, V., & Quevedo, J. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.05.007 · Cited by 221
“Additionally, approximately 50% of those who are diagnosed with MDD will experience a recurrent or chronic course of the illness (Crown et al., 2002).”
BackgroundStaging methods for treatment resistant depression. A systematic review
Ruhé, H. G., van Rooijen, G., Spijker, J., Peeters, F. P. M. L., & Schene, A. H. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.02.020 · Cited by 210
“Chronically depressed patients have a lower chance of recovery (Mueller and Leon, 1996), and often suffer from treatment resistant (refractory) depression (TRD) (Crown et al., 2002; Malhi et al., 2005).”
BackgroundZhou, X., Keitner, G. I., Qin, B., Ravindran, A. V., Bauer, M., Del Giovane, C., Zhao, J., Liu, Y., Fang, Y., Zhang, Y., et al. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv060 · Cited by 197
“Approximately 5–12% of males and 9–26% of females will suffer from at least one episode of depression over their lifetime, and about 50% of patients will experience a second depressive episode (Crown et al., 2002; Kessler et al., 2003; Finley, 2009).”
BackgroundMethodInfluentialResearch issues in the study of difficult-to-treat depression
Rush, A. J., Thase, M. E., & Dubé, S. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00088-x · Cited by 190
Self-citationEl-Khalili, N., Joyce, M., Atkinson, S., Buynak, R. J., Datto, C., Lindgren, P., & Eriksson, H. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000015 · Cited by 185
Li, C.-T., Bai, Y.-M., Huang, Y.-L., Chen, Y.-S., Chen, T.-J., Cheng, J.-Y., & Su, T.-P. (2012) · British Journal of Psychiatry · doi:10.1192/bjp.bp.110.086983 · Cited by 177
Recurrence of sickness absence due to common mental disorders
Koopmans, P. C., Bültmann, U., Roelen, C. A. M., Hoedeman, R., van der Klink, J. J. L., & Groothoff, J. W. (2011) · International Archives of Occupational and Environmental Health · doi:10.1007/s00420-010-0540-4 · Cited by 182
“Mental disorders have been reported to have a high risk of recurrence (Crown et al. 2002; Yonkers et al. 2003; Robinson and Sahakian 2008; Burcusa and Iacono 2007; Hardeveld et al. 2010), and this was conWrmed by our results.”
BackgroundResultIonescu, D. F., Bentley, K. H., Eikermann, M., Taylor, N., Akeju, O., Swee, M. B., Pavone, K. J., Petrie, S. R., Dording, C., Mischoulon, D., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.09.037 · Cited by 179
Tunnard, C., Rane, L. J., Wooderson, S. C., Markopoulou, K., Poon, L., Fekadu, A., Juruena, M., & Cleare, A. J. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.06.037 · Cited by 179
“TRD is also associated with greater social impairment (Kennedy and Paykel, 2004) and service utilisation (Crown et al., 2002).”
BackgroundPrevalence of treatment-resistant depression in primary care: cross-sectional data
Thomas, L., Kessler, D., Campbell, J., Morrison, J., Peters, T. J., Williams, C., Lewis, G., & Wiles, N. (2013) · British Journal of General Practice · doi:10.3399/bjgp13x675430 · Cited by 175
Chronotherapeutics in a psychiatric ward
Benedetti, F., Barbini, B., Colombo, C., & Smeraldi, E. (2007) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2007.06.004 · Cited by 165
A closer look at treatment resistant depression: is it due to a bipolar diathesis?
Sharma, V., Khan, M., & Smith, A. (2005) · Journal of Affective Disorders · doi:10.1016/j.jad.2004.01.015 · Cited by 164
“Patients with treatment resistant depression require more hospitalizations and are likely to receive more psychotropic medications (Crown et al., 2002).”
BackgroundBipolar depression: phenomenological overview and clinical characteristics
Mitchell, P. B., & Malhi, G. S. (2004) · Bipolar Disorders · doi:10.1111/j.1399-5618.2004.00137.x · Cited by 210
(2010) · PubMed · Cited by 157
Sajjadian, M., Lam, R. W. M., Milev, R. V., Rotzinger, S., Frey, B. N., Soares, C. N., Parikh, S. V., Foster, J. A., Turecki, G., Müller, D. J., et al. (2021) · Psychological Medicine · doi:10.1017/s0033291721003871 · Cited by 183
“Each treatment trial takes between 6 and 12 weeks and the delays are associated with the risk of adverse outcomes, including loss of employment and suicide (Al-Harbi, 2012; Crown et al., 2002).”
BackgroundAppelhof, B. C., Huyser, J., Verweij, M., Brouwer, J. P., van Dyck, R., Fliers, E., Hoogendijk, W. J. G., Tijssen, J. G. P., Wiersinga, W. M., & Schene, A. H. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.09.008 · Cited by 154
Ross, E. L., Zivin, K., & Maixner, D. F. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.0768 · Cited by 150
Fortunato, J. J., Réus, G. Z., Kirsch, T. R., Stringari, R. B., Stertz, L., Kapczinski, F., Pinto, J. P., Hallak, J. E., Zuardi, A. W., Crippa, J. A., et al. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.07.021 · Cited by 150
“…mood disorder do not respond actor; CDK, cyclin dependent ssion disorder (MDD); 5-HT2A, l rights reserved. adequately to the several currently available drugs (Crown et al., 2002), there is a clear need to develop and explore novel therapeutic agents for the management of MDD (Pacher et al., 2001).”
The Economic Burden of Treatment-Resistant Depression
Olchanski, N., McInnis Myers, M., Halseth, M., Cyr, P. L., Bockstedt, L., Goss, T. F., & Howland, R. H. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.09.001 · Cited by 146
Kubitz, N., Mehra, M., Potluri, R. C., Garg, N., & Cossrow, N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076882 · Cited by 143
“Crown et al [17] included for comparison with TRD patients, such patients that were ‘‘diagnosed with depression who met initial antidepressant medication dosage selection criteria but did not meet criteria for treatment resistance’’.”
BackgroundResultTabuteau, H., Jones, A., Anderson, A., Jacobson, M., & Iosifescu, D. V. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.21080800 · Cited by 140
Patkar, A. A., Masand, P. S., Pae, C.-U., Peindl, K., Hooper-Wood, C., Mannelli, P., & Ciccone, P. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000246212.03530.fd · Cited by 140
Healthcare and social services resource use and costs of self-harm patients
Sinclair, J., Gray, A. M., Rivero‐Arias, O., Saunders, K., & Hawton, K. E. (2010) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-010-0183-5 · Cited by 176
Berlim, M. T., McGirr, A., den Eynde, F. V., Fleck, M. P., & Giacobbe, P. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.02.016 · Cited by 149
“As a result, DBS is to be possibly offered to the most refractory cases of MD, although we believe that the availability of an expensive and invasive yet efficacious treatment is justifiable due to the enormous costs associated with chronic TRD (Crown et al., 2002; Russell et al., 2004).”
BackgroundIosifescu, D. V., Jones, A., O’Gorman, C., Streicher, C., Feliz, S., Fava, M., & Tabuteau, H. (2022) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.21m14345 · Cited by 135
Ivanova, J. I., Birnbaum, H. G., Kidolezi, Y., Subramanian, G., Khan, S. A., & Stensland, M. D. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.517716 · Cited by 131
“For the year 2000, Crown et al. (2002) estimated average annual costs to be $10,241 in the outpatient TRD group10.”
BackgroundMethodDefining Treatment-Resistant Depression: A Comprehensive Review of the Literature
Trevino, K., McClintock, S. M., Fischer, N. M., Vora, A., & Husain, M. M. (2014) · Annals of Clinical Psychiatry · doi:10.1177/104012371402600310 · Cited by 130
“23 TRD patients also used 1.4 to 3 times more psychotropic medications, which was significantly greater compared with non-TRD patients.”
InfluentialWang, R., Li, Y., Xu, Y., Li, Y., Wu, H., Guo, H., Zhang, J., Zhang, J., Pan, X., & Li, X.-J. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.10.016 · Cited by 139
“According to the recent report, the prevalence of depression has significantly increased 6% during the past 15 years (Crown et al., 2002).”
BackgroundWiles, N., Thomas, L., Abel, A., Barnes, M., Carroll, F., Ridgway, N., Sherlock, S., Turner, N., Button, K., Odondi, L., et al. (2014) · Health Technology Assessment · doi:10.3310/hta18310 · Cited by 127
Hall, S., Desbrow, B., Anoopkumar‐Dukie, S., Davey, A. K., Arora, D. S., McDermott, C., Schubert, M. M., Perkins, A. V., Kiefel, M. J., & Grant, G. D. (2015) · Food Research International · doi:10.1016/j.foodres.2015.07.027 · Cited by 139
“In addition to the high prevalence of this condition, literature shows that there is up to a 65% rate of failure with current antidepressant therapies (Crown et al., 2002; Fava, 2003; Fava et al., 2006; Paykel et al., 1995).”
López-Cruz, L., Salamone, J. D., & Correa, M. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00526 · Cited by 115
“, 2014), and it is widely accepted that at least 20% of all depressed patients do not respond adequately to most antidepressant drugs (Crown et al., 2002).”
BackgroundSleep Deprivation in Mood Disorders
Benedetti, F., & Colombo, C. (2011) · Neuropsychobiology · doi:10.1159/000328947 · Cited by 116
Noda, Y., Silverstein, W. K., Barr, M. S., Vila-Rodriguez, F., Downar, J., Rajji, T. K., Fitzgerald, P. B., Mulsant, B. H., Vigod, S. N., Daskalakis, Z. J., et al. (2015) · Psychological Medicine · doi:10.1017/s0033291715001609 · Cited by 115
“TRD is associated with significant economic and medical burden: medical costs are six times more for patients with TRD compared with patients with non-TRD ($42 344 v. $6512) (Crown et al. 2002).”
BackgroundDomany, Y., Bleich-Cohen, M., Tarrasch, R., Meidan, R., Litvak-Lazar, O., Stoppleman, N., Schreiber, S., Bloch, M., Hendler, T., & Sharon, H. (2019) · British Journal of Psychiatry · doi:10.1192/bjp.2018.196 · Cited by 114
Cusin, C., Ionescu, D. F., Pavone, K. J., Akeju, O., Cassano, P., Taylor, N., Eikermann, M., Durham, K., Swee, M. B., Chang, T., et al. (2017) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867416631828 · Cited by 111
“Perhaps most strikingly, patients with TRD are at a much greater risk for suicide attempts than those with treatmentresponsive depression (Crown et al., 2002).”
BackgroundOrsini, L. S., Rousculp, M. D., Long, S. R., & Wang, S. S. (2004) · Osteoporosis International · doi:10.1007/s00198-004-1694-2 · Cited by 111
“MarketScan data have been widely used for outcomes studies in a variety of therapeutic areas [14, 15, 16, 17].”
MethodWeisler, R., Joyce, J. M., McGill, L., Lazarus, A., Szamosi, J., Eriksson, H., & Moonstone Study Group (2009) · CNS Spectrums · doi:10.1017/s1092852900020307 · Cited by 108
“1) days for placebo; median(range): 26 (1-56) and 17 (1-56), respectively.”
The Impact of (the Concept of) Treatment-Resistant Depression: An Opinion Review
Demyttenaere, K., & Van Duppen, Z. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy052 · Cited by 98
“For TRD, the direct costs are even larger, resulting from higher chances of being hospitalized, more outpatient visits and more use of psychotropic medication (Crown et al., 2002).”
BackgroundAccelerated theta burst stimulation for the treatment of depression: a randomised controlled trial
Chen, L., Thomas, E. H. X., Kaewpijit, P., Miljevic, A., Hughes, R., Hahn, L., Kato, Y., Gill, S., Clarke, P., Ng, F., et al. (2021) · Brain Stimulation · doi:10.1016/j.brs.2021.07.018 · Cited by 105
“30 % have been reported [2], resulting in distress and disability for those living with depression, along with carer burden and health economic costs.”
BackgroundPerlis, R. H., Moorjani, P., Fagerness, J. A., Purcell, S., Trivedi, M. H., Fava, M., Rush, A. J., & Smoller, J. W. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.6 · Cited by 112
Self-citationSerafini, G., Pompili, M., Belvederi Murri, M., Respino, M., Ghio, L., Girardi, P., Fitzgerald, P. B., & Amore, M. (2015) · Neuropsychobiology · doi:10.1159/000381351 · Cited by 101
Therapeutic options in treatment-resistant depression
Vieta, E., & Colom, F. (2011) · Annals of Medicine · doi:10.3109/07853890.2011.583675 · Cited by 102
“TRD is a costly illness associated with a signifi cant increase in both medical and psychiatric heath care costs, both direct (medical treatments, hospitalizations) and indirect (lost work and decreased productivity) for patients and family members (4,5).”
BackgroundLight therapy in the treatment of patients with bipolar depression: A meta-analytic study
Tseng, P.-T., Chen, Y.-W., Tu, K.-Y., Chung, W., Wang, H.-Y., Wu, C.-K., & Lin, P.-Y. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.03.001 · Cited by 100
“At least 40% of depressive patients respond poorly to initial antidepressant therapy, and most of them respond unsatisfactorily to several types of antidepressants (Crown et al., 2002).”
BackgroundPaul, R., Schaaff, N., Padberg, F., Möller, H.-J., & Frodl, T. (2009) · The World Journal of Biological Psychiatry · doi:10.1080/15622970701714370 · Cited by 98
“To date, their clinical effectiveness is limited by the lag period of several weeks until clinical response and the considerable proportion of patients who does not respond sufficiently to treatment with several antidepressant drugs (Crown et al. 2002).”
BackgroundMaciel, I. D. S., Silva, R. B. M., Morrone, F. B., Calixto, J. Β., & Campos, M. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077227 · Cited by 114
“Additionally, many patients do not adhere to the existing therapy, because of the side effects of antidepressants [22,23].”
BackgroundSullivan, P. W., Valuck, R. J., Saseen, J. J., & MacFall, H. M. (2004) · CNS Drugs · doi:10.2165/00023210-200418130-00006 · Cited by 104
Comorbid anxiety corresponds with neuropsychological dysfunction in unipolar depression
Basso, M. R., Lowery, N., Ghormley, C., Combs, D., Purdie, R., Neel, J., Davis, M., & Bornstein, R. (2007) · Cognitive Neuropsychiatry · doi:10.1080/13546800701446517 · Cited by 96
“Similar studies involving depressed patients reveals earlier symptom onset, poorer outcomes, greater disability, and worse functional impairment in patients with other comorbid anxiety disorders than in those without one (Crown et al., 2002; Grunhaus, Pande, Brown, & Greden, 1994).”
BackgroundResultMauskopf, J. A., Simon, G. E., Kalsekar, A., Nimsch, C., Dunayevich, E., & Cameron, A. (2009) · Depression and Anxiety · doi:10.1002/da.20505 · Cited by 94
“Crown et al.([69]) in a database analysis showed that patients with treatment-resistant depression incurred TABLE 4.”
BackgroundDeep Brain Stimulation for Treatment-Resistant Depression
Holtzheimer, P. E., & Mayberg, H. S. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10010141 · Cited by 93
“Continued depressive symptoms are associated with ongoing functional impairment (4), increased utilization of health care resources (5), a greater risk of suicide (6), and an overall increased mortality (7).”
BackgroundSerious life events among resistant and non-resistant MDD patients
Amital, D., Fostick, L., Silberman, A., Beckman, M., & Спивак, Б. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.01.006 · Cited by 103
Lum, C. T., & Stahl, S. M. (2012) · CNS Spectrums · doi:10.1017/s1092852912000594 · Cited by 96
“Of those patients who were hospitalized, medical costs were 6 times those of the comparison group.(9) Currently, the U.”
ResultLam, R. W., Hossie, H., Solomons, K., & Yatham, L. N. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0308 · Cited by 88
Baune, B. T., Adrian, I., & Jacobi, F. (2007) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2006.09.014 · Cited by 96
“Although several previous studies confirm a significant effect of major depression on increased health care utilization due to depression [17,44–46], our findings, however, contribute unique results to the literature since our study shows that depression is associated with an excess of doctor visits even after adjusti…”
ResultIs unrecognized bipolar disorder a frequent contributor to apparent treatment resistant depression?
Correa, R., Akiskal, H. S., Gilmer, W. S., Nierenberg, A. A., Trivedi, M. H., & Zisook, S. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.06.036 · Cited by 101
“, 2007) burden of major depressive disorder (MDD) andmay even increasemortality (Crown et al., 2002; Yerevanian et al., 2007; Murray and Lopez, 1997; Wehr and Goodwin, 1987).”
BackgroundEffects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice
Falcon, E., Maier, K., Robinson, S. A., Hill-Smith, T. E., & Lucki, I. (2015) · Psychopharmacology · doi:10.1007/s00213-014-3723-y · Cited by 84
“The long-term economic impact of depression exceeds that of most other medical illnesses, in terms of work absenteeism and family burden (Crown et al. 2002).”
Wright, B. M., Eiland, E. H., & Lorenz, R. (2013) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1204 · Cited by 84
“Due to their favorable adverse event profiles, the SSRIs are the traditional choice for initial antidepressant therapy.1 It is estimated that one quarter to one third of patients reach symptom remission with monotherapy using a traditional antidepressant such as an SSRI.2 If a patient fails to respond adequately to th…”
BackgroundInfluentialQuetiapine augmentation of treatment-resistant depression: a comparison with lithium
Dorée, J.-P., Rosiers, J. D., Lew, V., Gendron, A., Elie, R., Stip, E., & Valérie Tourjman, S. (2007) · Current Medical Research and Opinion · doi:10.1185/030079906x162809 · Cited by 84
Fornaro, M., Carvalho, A. F., Fusco, A., Anastasia, A., Solmi, M., Berk, M., Sim, K., Vieta, E., & de Bartolomeis, A. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.07.109 · Cited by 86
Psilocybin and MDMA for the treatment of trauma-related psychopathology
Bird, C. I. V., Modlin, N. L., & Rucker, J. J. H. (2021) · International Review of Psychiatry · doi:10.1080/09540261.2021.1919062 · Cited by 80
“Treatment-resistant depression (TRD), defined as those who do not improve despite (usually) at least two established treatments (Strawbridge et al., 2019), develops in approximately 1/3 of those with a diagnosis of depression (Crown et al., 2002).”
BackgroundClarke, S., Kingston, J., James, K., Bolderston, H., & Remington, B. (2014) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2014.04.005 · Cited by 79
“Such clients consume a disproportionate amount of clinical resources (Amsterdam, Hornig, & Nierenberg, 2001; Crown et al., 2002; Russell et al., 2004) but, ironically, they are sometimes excluded from clinical trials to reduce variability and thus increase internal validity (Persons & Silberschatz,…”
Neuropsychologic effects of neuromodulation techniques for treatment-resistant depression: A review
Moreines, J. L., McClintock, S. M., & Holtzheimer, P. E. (2011) · Brain Stimulation · doi:10.1016/j.brs.2010.01.005 · Cited by 78
“Treatment-resistant depression (TRD) is therefore prevalent, resulting in added patient suffering, disability, and suicide risk (4,5).”
Aripiprazole in the Treatment of Depressive and Anxiety Disorders: A Review of Current Evidence
Pae, C., Serretti, A., Patkar, A. A., & Masand, P. S. (2008) · CNS Drugs · doi:10.2165/00023210-200822050-00002 · Cited by 85
“[2-4] However, the well known treatments.[1,2] Furthermore, approximately 50% of adverse effects of conventional antipsychotics have MDD patients and 40% of bipolar patients experi- limited their use in clinical practice.”
BackgroundIntravenous ketamine therapy in a patient with a treatment-resistant major depression
Liebrenz, M., Borgeat, A., & Leisinger, R. (2007) · Swiss Medical Weekly · doi:10.4414/smw.2007.11852 · Cited by 75
Bauer, M., Dell’Osso, L., Kasper, S. F., Pitchot, W., Vansvik, E. D., Köhler, J., Jørgensen, L., & Montgomery, S. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.05.079 · Cited by 75
“, 2008), the reduced costs associated with decreased hospitalisation and a return to productivity represent benefits of a more rapidly acting therapy (Crown et al., 2002; Montgomery et al., 2002).”
BackgroundNations, K. R., Dogterom, P., Bursi, R., Schipper, J., Greenwald, S., Zraket, D., Gertsik, L., Johnstone, J., Lee, A., Pande, Y., et al. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112458728 · Cited by 74
“However, given the heterogeneity of the disease, the patients who do not respond adequately are subject to multiple new medication trials or augmentation strategies to address their symptoms (Practice Guideline, American Psychiatric Association, 2010) and a significant proportion of depressed patients are still consid…”
BackgroundRepeated intravenous ketamine therapy in a patient with treatment-resistant major depression
Liebrenz, M., Stohler, R., & Borgeat, A. (2009) · The World Journal of Biological Psychiatry · doi:10.1080/15622970701420481 · Cited by 73
“It is widely accepted that at least 20% of all depressed patients do not respond adequately to several antidepressant drugs (Crown et al. 2002).”
BackgroundIntensive Short-Term Dynamic Psychotherapy of treatment-resistant depression: a pilot study
Abbass, A. A. (2006) · Depression and Anxiety · doi:10.1002/da.20203 · Cited by 72
“This pilot study examined the effectiveness of Intensive Short-term Dynamic Psychotherapy (ISTDP) in treatment-resistant depression (TRD).”
BackgroundInfluentialFanelli, G., Benedetti, F., Kasper, S., Zohar, J., Souery, D., Montgomery, S., Albani, D., Forloni, G., Ferentinos, P. P., Rujescu, D., et al. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110170 · Cited by 76
Familial Aggregation of Illness Chronicity in Recurrent, Early-Onset Major Depression Pedigrees
Mondimore, F. M., Zandi, P. P., MacKinnon, D. F., McInnis, M. G., Miller, E. B., Crowe, R. P., Scheftner, W. A., Marta, D. H., Weissman, M. M., Levinson, D. F., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1554 · Cited by 70
Aubry, J.-M., Gervasoni, N., Osiek, C., Perret, G., Rossier, M. F., Bertschy, G., & Bondolfi, G. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.07.007 · Cited by 58
Chronobiological Therapy for Mood Disorders
Dallaspezia, S., Suzuki, M., & Benedetti, F. (2015) · Current Psychiatry Reports · doi:10.1007/s11920-015-0633-6 · Cited by 76
Kopell, B. H., Halverson, J., Butson, C. R., Dickinson, M., Bobholz, J., Harsch, H., Rainey, C., Kondziolka, D., Howland, R., Eskandar, E., et al. (2011) · Neurosurgery · doi:10.1227/neu.0b013e318229cfcd · Cited by 68
Mansell, W., Colom, F., & Scott, J. L. (2005) · Clinical Psychology Review · doi:10.1016/j.cpr.2005.06.007 · Cited by 81
Yang, C., Wang, G., Wang, H., Liu, Z., & Wang, X. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.08.008 · Cited by 66
Economic Burden of Treatment-Resistant Depression on the U.S. Health Care System
Sussman, M., O’sullivan, A. K., Shah, A., Olfson, M., & Menzin, J. (2019) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2019.25.7.823 · Cited by 65
Identifying Difficult-to-Treat Depression: Differential Diagnosis, Subtypes, and Comorbidities
Gaynes, B. N. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.8133su1c.02 · Cited by 64
Pettit, J. W., Lewinsohn, P. M., Roberts, R. E., Seeley, J. R., & Monteith, L. (2009) · Psychological Medicine · doi:10.1017/s0033291708003851 · Cited by 63
“…are accompanied by psychosocial impairment in multiple domains, including economic standing, occupational performance, physical health status, social adjustment, and greater health-care costs (e.g. Hays et al. 1997 ; Berndt et al. 2000 ; Judd et al. 2000 ; Crown et al. 2002 ; Gilmer et al. 2005).”
BackgroundInteraction between the MTHFR C677T polymorphism and traumatic childhood events predicts depression
Lok, A., Bockting, C. L. H., Koeter, M. W. J., Snieder, H., Assies, J., Mocking, R. J. T., Vinkers, C. H., Kahn, R. S., Boks, M. P., & Schene, A. H. (2013) · Translational Psychiatry · doi:10.1038/tp.2013.60 · Cited by 63
Medicare patient experience with vagus nerve stimulation for treatment-resistant depression
Feldman, R. L., Dunner, D. L., Muller, J. S., & Stone, D. A. (2013) · Journal of Medical Economics · doi:10.3111/13696998.2012.724745 · Cited by 61
Chen, L., Hudaib, A., Hoy, K. E., & Fitzgerald, P. B. (2019) · Depression and Anxiety · doi:10.1002/da.22894 · Cited by 61
“…Wiley Periodicals, Inc. | 723 Despite their prevalence and negative impact on function and quality of life, both can be refractory to conventional treatments, with treatment resistance reported at rates of 30% for depressive (Crown et al., 2002) and 25% for anxiety disorders (Kessler et al., 2005).”
BackgroundAntidepressant-like behavioral effects of IGF-I produced by enhanced serotonin transmission
Hoshaw, B. A., Hill, T. I., Crowley, J. J., Malberg, J. E., Khawaja, X., Rosenzweig-Lipson, S., Schechter, L. E., & Lucki, I. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.07.023 · Cited by 60
“Introduction Major depressive disorder is currently one of the most prevalent and costly mood disorders (Crown et al., 2002).”
BackgroundMcIntyre, R. S., Millson, B., & Power, G. S. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.07.045 · Cited by 60
An Open-Label, Rater-Blinded, Augmentation Study of Aripiprazole in Treatment-Resistant Depression
Patkar, A. A., Peindl, K. S., Mago, R., Mannelli, P., & Masand, P. S. (2006) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v08n0205 · Cited by 63
Management of Treatment-Resistant Depression
Keitner, G. I., & Mansfield, A. K. (2011) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2011.11.004 · Cited by 70
Barr, C. E., Schulman, K. L., Iacuzio, D. A., & Bradley, J. S. (2007) · Current Medical Research and Opinion · doi:10.1185/030079906x167499 · Cited by 60
The economic impact of depression: Resistance or severity?
Fostick, L., Silberman, A., Beckman, M., Спивак, Б., & Amital, D. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.06.001 · Cited by 68
“Moreover, it was suggested that medical health care expenditures increase with the degree of TRD, i.e., the number of failed anti-depressive treatments (Crown et al., 2002; Russell et al., 2004).”
InfluentialIntravenous Ketamine for Treatment-Resistant Major Depressive Disorder
Covvey, J. R., Crawford, A. N., & Lowe, D. K. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1q371 · Cited by 58
Metadata
- Authors
- Crown, W. H., Finkelstein, S., Berndt, E. R., Ling, D., Poret, A. W., Rush, A. J., & Russell, J. M.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2002-11-15
- Volume
- 63
- Issue
- 11
- Pages
- 963-971
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2098750661
- Cited by
- 386
- References
- 0
- Citations by year
- 2026: 16 · 2025: 13 · 2024: 13 · 2023: 23 · 2022: 20 · 2021: 17 · 2020: 17 · 2019: 18 · 2018: 16 · 2017: 9 · 2016: 15 · 2015: 17 · 2014: 19 · 2013: 19 · 2012: 17
- FWCI
- 6.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- treatment-resistant depression, major depressive disorder, bipolar disorder, health care utilization, health care costs, antidepressants, hospitalization, psychotropic drug use, substance use comorbidity, anxiety disorders, health insurance claims data, suicide attempts, outpatient visits, chronic depression, recurrent depression
- MeSH terms
- Adult, Ambulatory Care, Bipolar Disorder, Costs and Cost Analysis, Depressive Disorder, Major, Major Depressive Disorder, Drug Resistance, Female, Humans, Male, Middle Aged, Patient Acceptance of Health Care, Patient Admission, Psychotropic Drugs, Referral and Consultation, Retrospective Studies, Utilization Review, Comorbidity, Drug Costs, Health Care Costs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.